Browse all 652 ETFs by category, no search needed
Global 184
US market 64
Country 92
Core UCITS 16
Sector 103
Style & factor 111
Theme 45
Dividend 37
ARK Genomic Revolution ETF (ARKG)
Look-through valuation · Theme · Expense ratio 0.75 % · ISIN US00214Q3020
Price history (since 2014)
Monthly close since 2014. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| 10X Genomics Inc TXG | 10.1 % | −70.3 % | 65 |
| Twist Bioscience Corp TWST | 9.2 % | n/a | n/a |
| Tempus AI, Inc. Class A Common Stock TEM | 7.2 % | n/a | n/a |
| Crispr Therapeutics AG CRSP | 6.1 % | −69.1 % | 30 |
| Personalis Inc PSNL | 5.5 % | n/a | n/a |
| Absci Corp ABSI | 5.2 % | n/a | n/a |
| Eli Lilly and Company LLY | 4.4 % | −68.1 % | 69 |
| Natera Inc NTRA | 4.3 % | −95.0 % | 37 |
| Guardant Health Inc GH | 4.3 % | n/a | n/a |
| CareDx Inc CDNA | 4.0 % | −79.2 % | 68 |
| Illumina Inc ILMN | 3.9 % | −50.5 % | 83 |
| Beam Therapeutics Inc BEAM | 3.5 % | n/a | n/a |
| Compass Pathways Plc CMPS | 3.3 % | n/a | n/a |
| Butterfly Network Inc BFLY | 2.6 % | −77.9 % | 38 |
| Adaptive Biotechnologies Corp ADPT | 2.5 % | n/a | n/a |
| Recursion Pharmaceuticals Inc RXRX | 2.5 % | −77.0 % | 22 |
| Nurix Therapeutics Inc NRIX | 2.4 % | n/a | n/a |
| Schrodinger Inc SDGR | 2.2 % | −76.8 % | 57 |
| Veracyte Inc VCYT | 2.2 % | −59.1 % | 71 |
| GeneDx Holdings Corp. WGS | 2.2 % | −94.2 % | 51 |
| Intellia Therapeutics Inc NTLA | 1.8 % | −78.9 % | 35 |
| Ionis Pharmaceuticals Inc IONS | 1.7 % | n/a | n/a |
| Alamar Biosciences, Inc. Common Stock ALMR | 1.5 % | n/a | n/a |
| Prime Medicine, Inc. Common Stock PRME | 1.3 % | n/a | n/a |
| Arcturus Therapeutics Holdings Inc ARCT | 1.1 % | −14.7 % | 41 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 32 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +71.9 % below FV
- 2 FXI iShares China Large-Cap ETF +53.7 % below FV
- 3 CHIQ Global X MSCI China Consumer Disc ETF +48.5 % below FV
- 4 FLCH Franklin FTSE China ETF +36.0 % below FV
- 5 KWEB KraneShares CSI China Internet ETF +33.5 % below FV
- 6 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +32.5 % below FV
- 7 MCHI iShares MSCI China ETF +28.0 % below FV
- 8 ITB iShares U.S. Home Construction ETF +13.7 % below FV
- 9 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +12.7 % below FV
- 10 TAN Invesco Solar ETF +10.8 % below FV
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives ARK Genomic Revolution ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Aug 14, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.